125I-labeled platinum nanoparticles

125I-labeled platinum nanoparticles are a novel **nanoparticle-based therapeutic agent** designed for combined chemo-radiotherapeutic treatment, in particular for hepatocellular carcinoma. The nanoparticles consist of platinum cores coated with the radioisotope iodine-125 (^125I), taking advantage of both platinum's chemotoxicity and the radiotoxicity through Auger electrons emitted by iodine-125 decay. This unique combination allows **selective tumor cell killing**: the high oxidative environment in HCC triggers the release of ^125I from the nanoparticles, leading to DNA damage via Auger electrons, while platinum nanoparticles catalyze additional oxidative stress via reactive oxygen species formation. The mechanism couples chemical cytotoxicity with localized radiotherapy at the DNA level, aiming to maximize tumor destruction while sparing surrounding healthy tissue. The agent is in preclinical development, most notably for application in hepatocellular carcinoma. It is not yet an approved pharmaceutical product and is explored primarily in academic and preclinical research settings[1][3][6].

Other names

125I–PtNPsiodine-125 labeled platinum nanoparticlesiodine125 labeled platinum nanoparticlesiodine 125 labeled platinum nanoparticles^125I–PtNPs125I-Pt NPs